<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03707652</url>
  </required_header>
  <id_info>
    <org_study_id>CL094</org_study_id>
    <nct_id>NCT03707652</nct_id>
  </id_info>
  <brief_title>Open-label Study to Assess Increasing Levels of NAD+(Nicotinamide Adenine Dinucleotide)</brief_title>
  <official_title>Three-Day Dosing NAD + Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Supplement Formulators, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Supplement Formulators, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess an effective single oral supplement or combination of
      oral supplements for increasing whole blood NAD+ levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a open-label dose finding study to detect an effective single oral supplement or
      combination of oral supplements for enhancing whole blood levels of NAD+. Each subject will
      receive a specific dose of the formulation once daily for 3 days followed by a washout
      period. Upon completion of the treatment phase, there is a post-treatment period of
      assessments.

      Participants receive assessments of blood tests, vital signs, body weight with completion of
      questionnaires.

      The primary objective of the study is to identify the ideal dosage of an oral supplement to
      increase whole blood NAD+ levels in adults.

      The secondary objective of the study is to monitor for safety from a change in fasting blood
      chemistry panel parameters after three day's dosing compared to cycle baseline.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 12, 2018</start_date>
  <completion_date type="Actual">May 24, 2018</completion_date>
  <primary_completion_date type="Actual">May 16, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the mean change in NAD+ levels from baseline</measure>
    <time_frame>63 days</time_frame>
    <description>Mean change in NAD+ levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the mean change in AST (aspartate aminotransferase) levels from baseline</measure>
    <time_frame>63 days</time_frame>
    <description>Mean change in AST level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the mean change in ALT (alanine aminotransferase) levels from baseline</measure>
    <time_frame>63 days</time_frame>
    <description>Mean change in ALT level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the mean change in Total Cholesterol levels from baseline</measure>
    <time_frame>63 days</time_frame>
    <description>Mean change in Total Cholesterol level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the mean change in Triglycerides levels from baseline</measure>
    <time_frame>63 days</time_frame>
    <description>Mean change in Triglycerides level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the mean change in LDL Cholesterol levels from baseline</measure>
    <time_frame>63 days</time_frame>
    <description>Mean change in LDL Cholesterol level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the mean change in HDL Cholesterol levels from baseline</measure>
    <time_frame>63 days</time_frame>
    <description>Mean change in HDL Cholesterol level</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Increase in Blood Levels of Nicotinamide Adenine Dinucleotide (NAD+)</condition>
  <arm_group>
    <arm_group_label>Cohort A (oral supplement A)-2 capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral supplement A (2 capsules) administered daily for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A (oral supplement B)-4 capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral supplement B (4 capsules) administered daily for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A (oral supplement C)-2 capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral supplement C (2 capsules) administered daily for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A (oral supplement A)-1 or 4 capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral supplement A (1 or 4 capsules) administered daily for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A (oral supplement D)-1 or 2 tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral supplement D (1 or 2 tablets) administered daily for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A (oral supplement D) or combination with supplement C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral supplement D (1 or 2 tablets) or combination with oral supplement C (2 or 4 capsules) administered daily for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B (oral supplement B)-4 capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral supplement B (4 capsules) administered daily for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B (oral supplement C)-2 capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral supplement C (2 capsules) administered daily for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B (oral supplement A)-2 capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral supplement A (2 capsules) administered daily for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B (oral supplement C)- 1 or 4 capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral supplement C (1 or 4 capsules) administered daily for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B (oral supplement D)-1 or 2 tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral supplement D (1 or 2 tablets) administered daily for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B(oral supplement D) or combination with supplement C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral supplement D (1 or 2 tablets) or combination with oral supplement C (2 or 4 capsules) administered daily for 3 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral supplement A</intervention_name>
    <description>1, 2 or 4 capsules daily of oral supplement A for 3 days</description>
    <arm_group_label>Cohort A (oral supplement A)-1 or 4 capsules</arm_group_label>
    <arm_group_label>Cohort A (oral supplement A)-2 capsules</arm_group_label>
    <arm_group_label>Cohort B (oral supplement A)-2 capsules</arm_group_label>
    <other_name>Vitamin B3 derivative</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral supplement B</intervention_name>
    <description>4 capsules daily of oral supplement B for 3 days</description>
    <arm_group_label>Cohort A (oral supplement B)-4 capsules</arm_group_label>
    <arm_group_label>Cohort B (oral supplement B)-4 capsules</arm_group_label>
    <other_name>Vitamin B3 derivative</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral supplement C</intervention_name>
    <description>1,2 or 4 capsules daily of oral supplement C for 3 days</description>
    <arm_group_label>Cohort A (oral supplement C)-2 capsules</arm_group_label>
    <arm_group_label>Cohort B (oral supplement C)- 1 or 4 capsules</arm_group_label>
    <arm_group_label>Cohort B (oral supplement C)-2 capsules</arm_group_label>
    <other_name>Vitamin B3 derivative</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral supplement D</intervention_name>
    <description>1 or 2 tablets daily of oral supplement D for 3 days</description>
    <arm_group_label>Cohort A (oral supplement D) or combination with supplement C</arm_group_label>
    <arm_group_label>Cohort A (oral supplement D)-1 or 2 tablets</arm_group_label>
    <arm_group_label>Cohort B (oral supplement D)-1 or 2 tablets</arm_group_label>
    <arm_group_label>Cohort B(oral supplement D) or combination with supplement C</arm_group_label>
    <other_name>Vitamin B3 derivative</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral Supplement D in combination with oral supplement C</intervention_name>
    <description>1 or 2 tablets of oral supplement D in combination with 2 or 4 capsules of oral supplement C for 3 days</description>
    <arm_group_label>Cohort A (oral supplement D) or combination with supplement C</arm_group_label>
    <arm_group_label>Cohort B(oral supplement D) or combination with supplement C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to provide written Informed Consent

          -  Able to follow verbal and written study directions in English

          -  Adult men and women between age 30-80 years (inclusive)

          -  Women of reproductive potential will practice contraception during the Investigation

          -  Body Mass Index (BMI) between 18.5 and 35 kg/m2

          -  Must not be taking or be willing to stop taking any supplements containing any form of
             niacin for seven days prior to baseline and for the duration of the study.

          -  Must not be using or be willing to stop use of any &quot;100%&quot; or higher niacin fortified
             foods from seven days prior to screening visit and for the duration of the
             investigation

          -  Able to maintain consistent diet and lifestyle habits throughout the study

          -  Volunteers with chronic but stable and well controlled medical conditions (i.e.,
             hypertension controlled by a consistent dose of medication for a minimum of six
             months; chronic use of consistent dose of blood-thinning medication; diet-controlled
             Type II diabetes) may participate at the discretion of the PI or Sub-I.

          -  Willing and able to provide fasting blood samples

          -  Able to attend scheduled visits at the Life Extension Clinical Research (LECR)
             facility

        Exclusion Criteria:

          -  Current use of prescription or over-the-counter nicotinic acid

          -  Use of statin drugs

          -  Having used any tobacco product or used a recreational drug in the past 6 months

          -  Medically complicated [i.e., diabetes requiring insulin; uncontrolled hypertension
             (blood pressure readings at screening/baseline &gt; 140 systolic or &gt; 90 diastolic on two
             consecutive readings); etc.] at the discretion of the PI or Sub-I

          -  Having abnormal screening laboratory test values or other lab test result(s) that
             would preclude study participation in the judgment of the PI or Sub-I

          -  Woman who is pregnant, nursing, or planning a pregnancy. Non-pregnant status of women
             of childbearing potential will be confirmed during each Day 3 Cycle LECR visit
             (Wednesday or Thursday) via serum pregnancy test.

          -  Currently, or within the past 30 days, enrolled in a different clinical investigation

          -  Inability to provide a venous blood sample

          -  Unable to refrain from any alcohol consumption for the duration of the study

          -  Unable or unwilling to provide written informed consent for participation in study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Swick, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>LIfe Extension</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Life Extension Clinical Research, Inc.</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kennedy BK, Berger SL, Brunet A, Campisi J, Cuervo AM, Epel ES, Franceschi C, Lithgow GJ, Morimoto RI, Pessin JE, Rando TA, Richardson A, Schadt EE, Wyss-Coray T, Sierra F. Geroscience: linking aging to chronic disease. Cell. 2014 Nov 6;159(4):709-13. doi: 10.1016/j.cell.2014.10.039.</citation>
    <PMID>25417146</PMID>
  </reference>
  <reference>
    <citation>Massudi H, Grant R, Braidy N, Guest J, Farnsworth B, Guillemin GJ. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One. 2012;7(7):e42357. doi: 10.1371/journal.pone.0042357. Epub 2012 Jul 27.</citation>
    <PMID>22848760</PMID>
  </reference>
  <reference>
    <citation>Verdin E. NAD‚Å∫ in aging, metabolism, and neurodegeneration. Science. 2015 Dec 4;350(6265):1208-13. doi: 10.1126/science.aac4854. Review.</citation>
    <PMID>26785480</PMID>
  </reference>
  <reference>
    <citation>Revollo JR, Grimm AA, Imai S. The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals. Curr Opin Gastroenterol. 2007 Mar;23(2):164-70. Review.</citation>
    <PMID>17268245</PMID>
  </reference>
  <reference>
    <citation>Yang H, Lavu S, Sinclair DA. Nampt/PBEF/Visfatin: a regulator of mammalian health and longevity? Exp Gerontol. 2006 Aug;41(8):718-26. Epub 2006 Jul 13. Review.</citation>
    <PMID>16842957</PMID>
  </reference>
  <reference>
    <citation>Gross CJ, Henderson LM. Digestion and absorption of NAD by the small intestine of the rat. J Nutr. 1983 Feb;113(2):412-20.</citation>
    <PMID>6218262</PMID>
  </reference>
  <reference>
    <citation>Knip M, Douek IF, Moore WP, Gillmor HA, McLean AE, Bingley PJ, Gale EA; European Nicotinamide Diabetes Intervention Trial Group. Safety of high-dose nicotinamide: a review. Diabetologia. 2000 Nov;43(11):1337-45. Review.</citation>
    <PMID>11126400</PMID>
  </reference>
  <reference>
    <citation>Airhart SE, Shireman LM, Risler LJ, Anderson GD, Nagana Gowda GA, Raftery D, Tian R, Shen DD, O'Brien KD. An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers. PLoS One. 2017 Dec 6;12(12):e0186459. doi: 10.1371/journal.pone.0186459. eCollection 2017.</citation>
    <PMID>29211728</PMID>
  </reference>
  <reference>
    <citation>Dellinger RW, Santos SR, Morris M, Evans M, Alminana D, Guarente L, Marcotulli E. Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD(+) levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study. NPJ Aging Mech Dis. 2017 Nov 24;3:17. doi: 10.1038/s41514-017-0016-9. eCollection 2017. Erratum in: NPJ Aging Mech Dis. 2018 Aug 20;4:8.</citation>
    <PMID>29184669</PMID>
  </reference>
  <reference>
    <citation>Trammell SA, Schmidt MS, Weidemann BJ, Redpath P, Jaksch F, Dellinger RW, Li Z, Abel ED, Migaud ME, Brenner C. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016 Oct 10;7:12948. doi: 10.1038/ncomms12948.</citation>
    <PMID>27721479</PMID>
  </reference>
  <reference>
    <citation>de Picciotto NE, Gano LB, Johnson LC, Martens CR, Sindler AL, Mills KF, Imai S, Seals DR. Nicotinamide mononucleotide supplementation reverses vascular dysfunction and oxidative stress with aging in mice. Aging Cell. 2016 Jun;15(3):522-30. doi: 10.1111/acel.12461. Epub 2016 Mar 11.</citation>
    <PMID>26970090</PMID>
  </reference>
  <reference>
    <citation>Mills KF, Yoshida S, Stein LR, Grozio A, Kubota S, Sasaki Y, Redpath P, Migaud ME, Apte RS, Uchida K, Yoshino J, Imai SI. Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice. Cell Metab. 2016 Dec 13;24(6):795-806. doi: 10.1016/j.cmet.2016.09.013. Epub 2016 Oct 27.</citation>
    <PMID>28068222</PMID>
  </reference>
  <reference>
    <citation>ClinicalTrials.gov. Effect of</citation>
  </reference>
  <reference>
    <citation>Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate, Other B Vitamins, and Choline. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. Washington (DC): National Academies Press (US); 1998.</citation>
    <PMID>23193625</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>October 11, 2018</study_first_submitted>
  <study_first_submitted_qc>October 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2018</study_first_posted>
  <last_update_submitted>October 16, 2018</last_update_submitted>
  <last_update_submitted_qc>October 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

